TAK vs GSK vs AZN vs NVS vs PFE

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). GSK plc (GSK) offers the better valuation at 6. 7x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Takeda Pharmaceutical Company Limited (TAK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GSK plc (GSK) is the cheapest at 6.

7x versus Takeda Pharmaceutical Company Limited at 76. 8x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Novartis AG's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +95.

1%, compared to -14. 8% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: AZN returned +269. 2% versus TAK's -2. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus AstraZeneca PLC's 0. 63β — meaning AZN is approximately 91% more volatile than TAK relative to the S&P 500. On balance sheet safety, AstraZeneca PLC (AZN) carries a lower debt/equity ratio of 61% versus 111% for GSK plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to -26. 2% for Takeda Pharmaceutical Company Limited. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 7. 5% for TAK. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Novartis AG's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 17. 8x for AstraZeneca PLC — 17. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZN: 15. 4% to $211. 00.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 7%, versus 1. 8% for AstraZeneca PLC (AZN).

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +179. 4% 10Y return). Both have compounded well over 10 years (NVS: +179. 4%, PFE: +28. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TAK is a mid-cap income-oriented stock; GSK is a mid-cap deep-value stock; AZN is a large-cap quality compounder stock; NVS is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.